Literature DB >> 2585886

Ischemic heart disease in systemic lupus erythematosus. A retrospective study of 65 patients treated with prednisolone.

G P Shome1, M Sakauchi, K Yamane, H Takemura, H Kashiwagi.   

Abstract

We studied the frequency of ST-T changes and ischemic heart disease (IHD) in prednisolone (PSL)-treated systemic lupus erythematosus (SLE) patients and compared them with the age-matched control of rheumatoid arthritis patients not receiving PSL. Twenty-five (38%) of the 65 SLE patients revealed ST-T changes as ST elevation (4%), ST depression (36%) and T wave flattening or inversion (60%). Among the control patients 4 (10%) had T wave flattening or inversion. The frequencies of ST-T changes in patients receiving total PSL dose of up to 5g and greater than 5g were 23% and 48%, respectively. Four patients developed IHD at an unusually young age during remission of SLE while receiving low dose of PSL and 2 of them later died of myocardial infarction (MI). The latter 2 patients had received PSL pulse therapy prior to MI. Regular ECG check up for SLE patients while they are on low dose PSL or pulse therapy may help reveal early ECG abnormalities and thus detect and treat one of the major risks of long-term effects of corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2585886     DOI: 10.2169/internalmedicine1962.28.599

Source DB:  PubMed          Journal:  Jpn J Med        ISSN: 0021-5120


  3 in total

1.  All-cause hospitalizations in systemic lupus erythematosus from a single medical center in Israel.

Authors:  Ofer Levy; Andrey Markov; Yulia Drob; Ilia Maslakov; Moshe Tishler; Mirit Amit-Vazina
Journal:  Rheumatol Int       Date:  2018-08-27       Impact factor: 2.631

Review 2.  Atherosclerosis and systemic lupus erythematosus.

Authors:  M Urowitz; D Gladman; I Bruce
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

3.  SLE - Practical and theoretical barriers to the prevention of accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  Karen H Costenbader; Matthew H Liang
Journal:  Arthritis Res Ther       Date:  2003-05-23       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.